SEC Comment Letter for OnKure Therapeutics, (OKUR) — Apr 30, 2026
OnKure Therapeutics, Inc.
Date: April 30, 2026 · CIK: 0001637715 · Accession: 0000000000-26-004422
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295304
Letter
Re: OnKure Therapeutics, Inc. Registration Statement on Form S-3 Filed April 24, 2026 File No. 333-295304 Dear Nicholas A. Saccomano:
April 30, 2026
Nicholas A. Saccomano President and Chief Executive Officer OnKure Therapeutics, Inc. 6707 Winchester Circle, Suite 400 Boulder, CO 80301
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Phillip McGill
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 30, 2026 Nicholas A. Saccomano President and Chief Executive Officer OnKure Therapeutics, Inc. 6707 Winchester Circle, Suite 400 Boulder, CO 80301 Re: OnKure Therapeutics, Inc. Registration Statement on Form S-3 Filed April 24, 2026 File No. 333-295304 Dear Nicholas A. Saccomano: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Phillip McGill </TEXT> </DOCUMENT>